Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: Donaldm who wrote (588)	3/28/1998 7:21:00 PM
From: Donaldm	Read Replies (2) \| Respond to of 965

The following was copied from AOL: Centocor Reports EPILOG Stent Data; ReoPro(R) abciximab) Reduces Ischemic Complications with Stents MALVERN, Pa., March 28 /PRNewswire/ -- Centocor, Inc. (Nasdaq: CNTO) announced today that the primary results of the EPILOG Stent trial will be reported on Tuesday, March 31, 1998 during the Late Breaking Trials session at the American College of Cardiology meeting in Atlanta. In this Phase III trial, both ReoPro-treated groups showed a statistically significant improvement versus patients receiving stents without ReoPro in the composite primary endpoint of death, heart attack or urgent intervention at 30 days. The composite endpoint was reduced by more than one-third in the ReoPro plus percutaneous transluminal coronary angioplasty (PTCA) arm and by one-half in the ReoPro plus stent group. "We are pleased with the ReoPro clinical trial results," said Joseph C. Scodari, president and chief operating officer. "There are now four Phase III clinical trials, with over 8,000 patients studied, consistently demonstrating that ReoPro reduces death and heart attack by a statistically significant margin." EPILOG Stent was a multicenter, double-blind, placebo-controlled trial designed to compare three treatment strategies in patients in need of percutaneous coronary revascularization. The primary composite endpoint was the reduction of the incidence of death, myocardial infarction, or urgent intervention at 30 days. A total of 2,399 patients at 63 sites were randomized into three treatment arms: placebo and intracoronary stent implantation; ReoPro plus intracoronary stent implantation, and; ReoPro plus conventional PTCA. Placebo patients received aspirin and standard weight-adjusted heparin doses, whereas ReoPro patients received aspirin and reduced weight-adjusted heparin doses. Patients receiving stents also received ticlopidine following the procedure. ReoPro was developed by Centocor, Inc., and is manufactured by Centocor B.V. in Leiden, The Netherlands. Eli Lilly and Company distributes the product worldwide, except in Japan. Fujisawa Pharmaceutical Company, Ltd. will distribute ReoPro upon approval in Japan. Centocor is a biopharmaceutical company that develops or acquires and commercializes novel therapeutic and diagnostic products that solve critical needs in human healthcare. The company's primary technology focus is on monoclonal antibodies and DNA-based products. Full prescribing information for ReoPro can be found on the Centocor web site at www.centocor.com. Any statements released by Centocor that are forward looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations, estimates and projections about the Company's industry, management's beliefs and certain assumptions made by the Company's management. Investors are cautioned that matters subject to forward-looking statements involve risks and uncertainties which may affect the Company's business and prospects, including economic, competitive, government, technological and other factors discussed in the Company's filings with the Securities and Exchange Commission. Investors are cautioned, in particular, that there can be no assurance of favorable regulatory action by the U.S. Food and Drug Administration and other regulatory bodies based on the results of this clinical trial. ReoPro is a registered trademark of Eli Lilly and Company. SOURCE Centocor, Inc. CO: Centocor, Inc. ST: Pennsylvania IN: MTC SU: PDT 03/28/98 18:00 EST prnewswire.com